These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28121713)

  • 21. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
    Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
    J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
    Zhao L; Tong P; Chen YX; Hu ZW; Wang K; Zhang YN; Zhao DS; Cai LF; Liu KL; Zhao YF; Li YM
    Org Biomol Chem; 2012 Aug; 10(32):6512-20. PubMed ID: 22760295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry.
    Wang X; Xiong W; Ma X; Wei M; Chen Y; Lu L; Debnath AK; Jiang S; Pan C
    PLoS One; 2012; 7(9):e44874. PubMed ID: 22970321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
    Liu S; Jing W; Cheung B; Lu H; Sun J; Yan X; Niu J; Farmar J; Wu S; Jiang S
    J Biol Chem; 2007 Mar; 282(13):9612-9620. PubMed ID: 17276993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thermodynamic dissection of the interface between HIV-1 gp41 heptad repeats reveals cooperative interactions and allosteric effects.
    Jurado S; Cano-Muñoz M; Polo-Megías D; Conejero-Lara F; Morel B
    Arch Biochem Biophys; 2020 Jul; 688():108401. PubMed ID: 32376316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action.
    Wexler-Cohen Y; Shai Y
    PLoS Pathog; 2009 Jul; 5(7):e1000509. PubMed ID: 19593361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probing Vulnerability of the gp41 C-Terminal Heptad Repeat as Target for Miniprotein HIV Inhibitors.
    Jurado S; Moog C; Cano-Muñoz M; Schmidt S; Laumond G; Ruocco V; Standoli S; Polo-Megías D; Conejero-Lara F; Morel B
    J Mol Biol; 2020 Sep; 432(20):5577-5592. PubMed ID: 32822695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.
    Su S; Ma Z; Hua C; Li W; Lu L; Jiang S
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29156603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
    Korazim O; Sackett K; Shai Y
    J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
    Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
    AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.
    Chong H; Yao X; Qiu Z; Qin B; Han R; Waltersperger S; Wang M; Cui S; He Y
    J Biol Chem; 2012 Jun; 287(24):20281-9. PubMed ID: 22511760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation.
    Zhao L; Hu ZW; Tong P; Chen YX; Zhao YF; Li YM
    Bioorg Med Chem Lett; 2013 May; 23(9):2727-32. PubMed ID: 23522564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
    Nomura W; Hashimoto C; Suzuki T; Ohashi N; Fujino M; Murakami T; Yamamoto N; Tamamura H
    Bioorg Med Chem; 2013 Aug; 21(15):4452-8. PubMed ID: 23800723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C; Liu S; Jiang S
    J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conformational flexibility of the conserved hydrophobic pocket of HIV-1 gp41. Implications for the discovery of small-molecule fusion inhibitors.
    Cano-Muñoz M; Jurado S; Morel B; Conejero-Lara F
    Int J Biol Macromol; 2021 Dec; 192():90-99. PubMed ID: 34619276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.
    Louis JM; Baber JL; Clore GM
    Biochemistry; 2015 Nov; 54(45):6796-805. PubMed ID: 26506247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs.
    Crespillo S; Cámara-Artigas A; Casares S; Morel B; Cobos ES; Mateo PL; Mouz N; Martin CE; Roger MG; El Habib R; Su B; Moog C; Conejero-Lara F
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18207-12. PubMed ID: 25489108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Swapped-domain constructs of the glycoprotein-41 ectodomain are potent inhibitors of HIV infection.
    Chu S; Kaur H; Nemati A; Walsh JD; Partida V; Zhang SQ; Gochin M
    ACS Chem Biol; 2015 May; 10(5):1247-57. PubMed ID: 25646644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
    Liu Y; Ke Z; Wu KY; Liu S; Chen WH; Jiang S; Jiang ZH
    ChemMedChem; 2011 Sep; 6(9):1654-64. PubMed ID: 21688394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.